Weedstocks Newswire Feed
CSE: HC OTC: HHPHF FSE: 0HCN
Acquisition adds near-term revenue and creates notable benefits through synergies within High Hampton's growing portfolio of subsidiaries
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES./
TORONTO, Nov. 12, 2018 /CNW/ - High Hampton Holdings Corp. (CSE: HC) (FSE: 0HCN) ("High Hampton" or the "Company") is pleased to report that it has successfully closed the previously announced transaction to acquire 100% of all of the issued and outstanding member interests in Mojave Jane, LLC ("Mojave Jane") (the "Acquisition"). The Acquisition adds a fifth 100%-owned subsidiary to High Hampton's growing portfolio of California-based cannabis manufacturers and distributors, and, in addition to profits already generating from its other brands, is also expected to add near-term revenue to the Company's bottom line.
Mojave Jane, LLC is a California licensed manufacturer of premium cannabis extracts and concentrates for the California markets. Based in Coachella, CA, and licensed for both volatile and non-volatile manufacturing, Mojave Jane currently utilizes state of the art CO2 extraction technologies and proven distillation techniques to create products for both recreational and medical cannabis users. Mojave Jane's management team includes an accomplished group of business executives with experience in starting, growing, and selling companies, combined with hands-on commercial cannabis experience. Mojave Jane is a key part of the Coachella Valley's growing cannabis economy and supports distribution throughout California.
GATINEAU, Quebec, Nov. 09, 2018 (GLOBE NEWSWIRE) -- HEXO Corp. (“HEXO” or the “Company”) (TSX:HEXO) announced that it has filed a preliminary short form base shelf prospectus with the securities regulatory authorities in each of the provinces and territories of Canada.
The shelf prospectus will enable HEXO to make offerings of up to $800 million of common shares, warrants, subscription receipts and units or a combination thereof of the Company from time to time, separately or together, in amounts, at prices and on terms to be determined based on market conditions at the time of the offering and as set out in an accompanying prospectus supplement, during the 25-month period that the shelf prospectus, when made final, remains valid. The specific terms of any future offering will be established in a prospectus supplement to the shelf prospectus, which supplement will be filed with the applicable Canadian securities regulatory authorities. Unless otherwise specified in the prospectus supplement relating to a particular offering of securities, the net proceeds from any sale of any securities may be used by HEXO for general corporate purposes, including funding ongoing operations and/or working capital requirements, to repay indebtedness from time to time, capital projects and potential future acquisitions, including in relation to international expansion.
A copy of the preliminary short form base shelf prospectus can be found on SEDAR at www.sedar.com.
About HEXO Corp.
HEXO Corp. creates and distributes innovative, easy-to-use and easy-to-understand products to serve the Canadian cannabis market. One of the country’s lowest-cost producers, HEXO is rapidly increasing its production capacity in the lead up to the adult-use cannabis market. The Company currently operates with over 310,000 sq. ft. of production capacity with construction on another 1,000,000 sq. ft. expansion set to be complete by year end. HEXO will serve the adult-use market under the HEXO brand, while continuing to serve its medical cannabis clients through the well-known Hydropothecary brand.
GATINEAU, Québec, 09 nov. 2018 (GLOBE NEWSWIRE) -- HEXO Corp. (« HEXO » ou la « Société ») (TSX: HEXO) a annoncé le dépôt d’un prospectus préalable de base simplifié provisoire auprès des autorités de réglementation en valeurs mobilières de chacune des provinces et chacun des territoires du Canada.
Le prospectus préalable permettra à HEXO d’émettre jusqu’à 800 millions de dollars d’actions ordinaires, de bons de souscription, de reçus de souscription et de parts de la Société ou une combinaison de ces titres, de temps à autre, séparément ou ensemble, en quantités, à des prix et selon des modalités à déterminer en fonction des conditions du marché au moment du placement et de la façon indiquée dans un supplément de prospectus ci-joint, au cours de la période de 25 mois pendant laquelle le prospectus préalable, lorsqu’il sera rendu définitif, restera en vigueur. Les conditions exactes de tout placement futur seront établies dans un supplément de prospectus au prospectus préalable, lequel supplément sera déposé auprès des autorités canadiennes en valeurs mobilières pertinentes. Sauf indication contraire dans le supplément de prospectus relatif à un placement de titres, le produit net de toute vente de valeurs mobilières peut être utilisé par HEXO à des fins générales de la Société, y compris pour le financement des opérations en cours et/ou les besoins en fonds de roulement, pour rembourser des dettes de temps à autre, pour les projets d’équipement et pour les acquisitions potentielles futures, y compris en ce qui concerne une expansion internationale.
Une copie du prospectus préalable de base simplifié provisoire est disponible sur SEDAR à l’adresse www.sedar.com
À propos de HEXO Corp.
HEXO Corp. crée et distribue des produits novateurs, faciles à utiliser et à comprendre pour servir le marché canadien du cannabis. L'un des producteurs les moins chers au pays, HEXO augmente rapidement sa capacité de production dans la perspective du marché du cannabis chez les adultes. La Société exploite actuellement une capacité de production de plus de 310 000 pieds carrés et a un autre agrandissement de 1 000 000 pieds carrés présentement en construction qui devrait être terminé d'ici la fin de l'année. HEXO desservira le marché de l'usage adulte sous la marque HEXO, tout en continuant à servir ses clients du cannabis médical par l'entremise de la célèbre marque Hydropothecary.
VAUGHAN, ON, Nov. 9, 2018 /CNW/ - CannTrust Holdings Inc. ("CannTrust" or the "Company") (TSX: TRST), one of Canada's leading and most trusted licensed producers of cannabis, plans to release its financial results for the third quarter ended September 30, 2018 on Wednesday, November 14, 2018 after market close. The Company will host a conference call the same day at 5:00 p.m. ET to discuss its third quarter financial results and provide investors with key business highlights. The call will be hosted by Peter Aceto, Chief Executive Officer and Ian Abramowitz, Chief Financial Officer.
CONFERENCE CALL DETAILS
Date: November 14, 2018 | Time: 5:00 p.m. EST
Participant Dial-in: (+1) 416 764 8609 or (+1) 888 390 0605
Conference ID: 84565275
VANCOUVER, Nov. 9, 2018 /CNW/ - Bougainville Ventures Inc. ("Bougainville" or the "Company") is pleased to announce that it has arranged a private placement (the "Private Placement") of units (each a "Unit") at a price of $0.20 per Unit for gross proceeds of up to $1,000,000. The Company has made an allowance for an oversubscription of up to 100% of the expected gross proceeds of $1,000,000.
Each Unit is comprised of one common share (each a "Share") of the Company and one common share purchase warrant (each a "Warrant"). Each Warrant entitles the holder to purchase one additional common share (each a "Warrant Share") of the Company at an exercise price of $0.30 per Warrant Share for a term that is 24 months from the date of closing of the Private Placement.
The proceeds of the Private Placement will be used for general working capital.
The Company wishes to correct a typo in its news release dated October 31, 2018, in which it announced the closing of a previously announced private placement with gross proceeds of $308,000 and 1,232,000 units. The previously announced private placement closed with gross proceeds of $320,500 and 1,282,000 units.
About Bougainville Ventures, Inc. Bougainville provides cannabis infrastructure and seed-to-sale services to I-502 tenant-growers leasing greenhouse facilities space and providing fully built-out, turnkey solutions and ancillary services including processing, cannabis expertise and marketing and sales resources. Greenhouse canopies provide a 50% saving in cultivation cost.
Xanthic Biopharma and Green Growth Brands Announce Closing of Business Combination and Conditional Approval from the CSE
/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/
TORONTO, Nov. 9, 2018 /CNW/ - Xanthic Biopharma Inc. (formerly Aurquest Resources Inc.) ("Xanthic") (CSE: xTHC) and Green Growth Brands Inc. ("GGB") are pleased to announce that they have completed the previously announced Business Combination (defined below) between Xanthic and GGB (see The Business Combination below). Following closing, Xanthic will continue under the corporate name "Xanthic Biopharma Inc." until the first quarter of 2019, following which time it is expected to change its corporate name to "Green Growth Brands Ltd." (the combined entity, following completion of the Business Combination is referred to as "we", the "Company" or the "Resulting Issuer"). Until such time the Company will operate in Ontario under the business name "Green Growth Brands".
It is anticipated that the common shares of the Company will resume trading on the facilities of the Canadian Securities Exchange under the ticker symbol "GGB" on November 13, 2018 (see Conditional Listing Approval below).
"The completion of the business combination gives retail and institutional investors a chance to participate in our growth story as we build a premium North American retailer of cannabis, THC and CBD products," said Peter Horvath, CEO of the Company's operating entity. "We have built and led industry-leading retail organizations before, and we will do it again by keeping the consumer at the center of everything we do."
About the Company:
TORONTO, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Wayland Group (CSE:WAYL) (FRANKFURT: 75M) (OTCQB:MRRCF) (“Wayland” or the “Company”) is pleased to announce it has completed a definitive joint venture agreement with CBD Italian Factory S.S., a company of Group San Martino for the production of high quality cannabis products in Italy.
The joint venture will marry the best of both entities with world-leading technology by Rockwell Automation paired with existing infrastructure in Piedmont, Italy, which includes agricultural expertise and biogas electricity. This will allow the sustainable production of quality CBD and THC products from a naturally derived fuel source.
CBD Italian Factory S.S. and San Martino Group will bring mass-scale agricultural skills to the joint venture with a focus on local sustainable practices and expertise in Biomass Energy production. The joint venture will be a split of 50.1% (Wayland)/49.9% (CBD Italian Factory) with Massimiliano Umberto Signorini assuming the role of CEO for the new company.
Wayland Group has identified that Europe is an important market for cannabis with over 742 million people and combined gross domestic product of EUR 15.3 trillion with the cannabis market forecast to be worth EUR 115.7 billion by 2028.i The Company is familiar with and able to navigate the strict European regulatory framework and complex licensing process, as proven by EU-GMP certification of its Canadian facilities. The Company believes that joint ventures such as this are key to gaining first mover advantage in a growing market through working with trusted in-country partners to gain speed to market.
“We are now well positioned in the Italian market for CBD and potential THC production. We are proud to partner with Umberto Signorini to build on the strong business and agricultural platform they have established in Milan and Piedmont.” said Ben Ward, Chief Executive Officer of Wayland.
View from the C-Suite: Pat McCutcheon, President and CEO, MediPharm Labs Corp., tells his company's story. Filmed on October 5, 2018
TORONTO, Nov. 9, 2018 /CNW/ -
The View from the C-Suite video interview series highlights the unique perspectives of listed companies on Toronto Stock Exchange and TSX Venture Exchange. Videos provide insight into how company executives think in the current business environment. To see the latest View from the C-Suite videos visit www.tmxmoney.com/en/news/csuite.html)
About MediPharm Labs Corp. (TSXV: LABS)
Founded in 2015, MediPharm Labs is a pioneer in the cannabis industry and has the distinction of being the first company in Canada to become a licensed producer for cannabis oil production under the Access to Cannabis for Medical Purposes Regulations (ACMPR) without first receiving a cannabis cultivation licence. This expert focus on cannabis concentrates from our cGMP (current Good Manufacturing Practices) and ISO standard clean rooms and critical environments laboratory, allows MediPharm Labs to work with its established, Health Canada-approved cultivation partners to produce pharmaceutical-grade cannabis oil with a competitive advantage. MediPharm Labs is research-driven and focused on downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification. MediPharm Labs provides B2B contract processing of cannabis to Canadian authorized licensed producers and appropriate international growers, supplying integrity-assured cannabis oil to qualified companies for sale under their own brand. In addition, MediPharm Labs will supply raw materials, formulations, processing and packaging for the creation of ready-to-sell advanced derivative products.
Gabriella's Kitchen Inc. Discusses Proposed Changes to California's Cannabis Regulations, Jeff Sessions' Resignation as US Attorney General and Other Legal Developments
/THIS PRESS RELEASE IS NOT FOR PUBLICATION OR DISSEMINATION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW./
CALGARY and SANTA ROSA, CA, Nov. 9, 2018 /CNW/ - Gabriella's Kitchen Inc. (the "Company" or "GABY") (CSE: GABY) today provided comments to shareholders on recent changes in United States cannabis regulations, plus other national and international developments in the cannabis sector.
GABY commented to shareholders today on recent draft regulations that have been released by the California Bureau of Cannabis Control ("CBCC") which prohibit white labelling and co-packing of cannabis infused products for companies not holding a license issued by the CBCC. If passed, brands not holding a manufacturing license would not be allowed to manufacture infused products for sale in the state of California. GABY recently acquired two cannabis licenses, a manufacturing license through its acquisition of The Oil Plant and a distribution license through its acquisition of Sonoma Pacific Distribution (both issued by the CBCC).
"It has always been part of GABY's strategy to own its infrastructure in California and to control its product development and sales cycle" said Margot Micallef, Founder & CEO of GABY. "With these two licenses GABY is protected from the vagaries of legislative changes such as those draft regulations recently introduced" she added.
"While we do not want to see any of the great brands offered in California cut off from being able to access the California markets - to the degree that it makes sense - we are poised to acquire such brands who wish to partner with GABY to protect their market share through GABY's manufacturing license and to expand with GABY's mainstream and licensed distribution infrastructure" Ms. Micallef concluded.
VANCOUVER, Nov. 9, 2018 /CNW/ - 1933 Industries Inc. (the "Company" or "1933 Industries") (CSE: TGIF) (OTCQB: TGIFF) a licensed cultivator and producer of cannabis flower and concentrates and manufacturer of hemp/CBD wellness products, is pleased to announce that it will have a strong presence as a Silver Sponsor of the upcoming Marijuana Business Conference ('MJBizCon") in Las Vegas, Nevada.
The MJBizCon is the largest cannabis conference in the world, where over 20,000 cannabis professionals will meet under one roof to exhibit and promote the industry. The conference opens its door on November 14 and runs until November 16 at the Las Vegas Convention Centre.
Alternative Medicine Association is one of Nevada's largest wholesaler of cannabis concentrates, and its products include branded flower, wholesale distillate for vape products, and a broad range of concentrates (crumble, shatter, sugar, wax, oils, etc.), as well as white label production for third party leading brands. Infused MFG. manufactures proprietary hemp-based, CBD products under the Canna Hemp™, Canna HempX™, Canna Hemp Paws™ and Canna Fused™ lines. Both subsidiaries of the Company will be exhibiting their extensive product lines to a captive audience. Executives from the Company's advisory firm, Spire Global Strategy, will be attending the conference and will be available to discuss risk management, due diligence, security, compliance and intelligence services in the sector.
"All the major players, investors and thought leaders in the cannabis space will be gathering at MJBizCon to drive business deals and to foster collaborative relationships", remarked Mr. Chris Rebentisch, US Chief of Operations, Infused MFG. Founder and Director of 1933 Industries. "As the first licensed cultivator in Las Vegas, we have deep roots in this city and we welcome representatives from around the world to the largest professional conference of its kind."
Please visit the 1933 Industries booth #3729 at MJBizCon.